OKYO
OKYO Pharma Limited
Biotechnology
Market Cap$66M
5Y Perf.-21.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
OKYO vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$1.92B
5Y Perf.-79.1%
OKYO vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | OKYO | NVCR |
|---|---|---|
| Industry | Biotechnology | Medical - Instruments & Supplies |
| Market Cap | $66M | $1.92B |
| Revenue (TTM) | $0.00 | $674M |
| Net Income (TTM) | $-5M | $-173M |
| Gross Margin | — | 75.2% |
| Operating Margin | — | -27.2% |
| Total Debt | $0.00 | $290M |
| Cash & Equiv. | $2M | $103M |
OKYO vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
OKYO
NVCR
| Stock | May 22 | May 26 | Return |
|---|---|---|---|
| OKYO Pharma Limited (OKYO) | 100 | 79.0 | -21.0% |
| NovoCure Limited (NVCR) | 100 | 20.9 | -79.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OKYO vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: OKYO leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. NovoCure Limited is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
OKYO
OKYO Pharma Limited
The Income Pick
OKYO carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 0.79
- Lower volatility, beta 0.79, current ratio 0.40x
- Beta 0.79, current ratio 0.40x
Best for: income & stability and sleep-well-at-night
NVCR
NovoCure Limited
The Growth Play
NVCR is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 8.3%, EPS growth 21.8%, 3Y rev CAGR 6.8%
- 30.3% 10Y total return vs OKYO's -55.2%
- 8.3% revenue growth vs OKYO's -11K%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NVCR | 8.3% revenue growth vs OKYO's -11K% |
| Quality / Margins | OKYO | -23.9% margin vs NVCR's -25.7% |
| Stability / Safety | OKYO | Beta 0.79 vs NVCR's 2.20 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | OKYO | +10.2% vs NVCR's +1.1% |
| Efficiency (ROA) | NVCR | -16.5% ROA vs OKYO's -128.4% |
OKYO vs NVCR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLOKYOLAGGINGNVCR
NVCRNovoCure Limited
1leads
OKYOOKYO Pharma Limited
3leads
6 Total Categories
CATEGORYLEADERvs NVCRMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
OKYO1/1
Valuation MetricsMultiples, price ratios, and targets
NVCR1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
OKYO3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
OKYO4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
OKYO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NVCR and OKYO operate at a comparable scale, with $674M and $0 in trailing revenue.
| Metric | OKYOOKYO Pharma Limit… | NVCRNovoCure Limited |
|---|---|---|
| RevenueTrailing 12 months | $0 | $674M |
| EBITDAEarnings before interest/tax | -$4M | -$165M |
| Net IncomeAfter-tax profit | -$5M | -$173M |
| Free Cash FlowCash after capex | -$2M | -$48M |
| Gross MarginGross profit ÷ Revenue | — | +75.2% |
| Operating MarginEBIT ÷ Revenue | — | -27.2% |
| Net MarginNet income ÷ Revenue | — | -25.7% |
| FCF MarginFCF ÷ Revenue | — | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +83.3% | -100.0% |
OKYO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
NVCR leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | OKYOOKYO Pharma Limit… | NVCRNovoCure Limited |
|---|---|---|
| Market CapShares × price | $66M | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $64M | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | -13.50x | -13.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 2.92x |
| Price / BookPrice ÷ Book value/share | — | 5.51x |
| Price / FCFMarket cap ÷ FCF | — | — |
NVCR leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
OKYO leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), NVCR scores 5/9 vs OKYO's 3/9, reflecting solid financial health.
| Metric | OKYOOKYO Pharma Limit… | NVCRNovoCure Limited |
|---|---|---|
| ROE (TTM)Return on equity | — | -50.8% |
| ROA (TTM)Return on assets | -128.4% | -16.5% |
| ROICReturn on invested capital | — | -16.4% |
| ROCEReturn on capital employed | — | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | — | 0.85x |
| Net DebtTotal debt minus cash | -$2M | $187M |
| Cash & Equiv.Liquid assets | $2M | $103M |
| Total DebtShort + long-term debt | $0 | $290M |
| Interest CoverageEBIT ÷ Interest expense | -8.03x | -96.80x |
OKYO leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
OKYO leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in OKYO five years ago would be worth $4,475 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, OKYO leads with a +10.2% total return vs NVCR's +1.1%. The 3-year compound annual growth rate (CAGR) favors OKYO at -8.7% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | OKYOOKYO Pharma Limit… | NVCRNovoCure Limited |
|---|---|---|
| YTD ReturnYear-to-date | -27.4% | +28.3% |
| 1-Year ReturnPast 12 months | +10.2% | +1.1% |
| 3-Year ReturnCumulative with dividends | -23.9% | -75.7% |
| 5-Year ReturnCumulative with dividends | -55.2% | -91.3% |
| 10-Year ReturnCumulative with dividends | -55.2% | +30.3% |
| CAGR (3Y)Annualised 3-year return | -8.7% | -37.6% |
OKYO leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — OKYO and NVCR each lead in 1 of 2 comparable metrics.
Risk & Volatility
OKYO is the less volatile stock with a 0.79 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs OKYO's 48.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OKYOOKYO Pharma Limit… | NVCRNovoCure Limited |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.79x | 2.20x |
| 52-Week HighHighest price in past year | $3.35 | $20.06 |
| 52-Week LowLowest price in past year | $1.32 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +48.4% | +83.9% |
| RSI (14)Momentum oscillator 0–100 | 54.9 | 69.8 |
| Avg Volume (50D)Average daily shares traded | 93K | 1.5M |
Evenly matched — OKYO and NVCR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | OKYOOKYO Pharma Limit… | NVCRNovoCure Limited |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $33.50 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
OKYO leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). NVCR leads in 1 (Valuation Metrics). 1 tied.
Best OverallOKYO Pharma Limited (OKYO)Leads 3 of 6 categories
Loading custom metrics...
OKYO vs NVCR: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is OKYO or NVCR a better buy right now?
Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OKYO or NVCR?
Over the past 5 years, OKYO Pharma Limited (OKYO) delivered a total return of -55.
2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus OKYO's -55. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OKYO or NVCR?
By beta (market sensitivity over 5 years), OKYO Pharma Limited (OKYO) is the lower-risk stock at 0.
79β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 178% more volatile than OKYO relative to the S&P 500.
04Which has better profit margins — OKYO or NVCR?
OKYO Pharma Limited (OKYO) is the more profitable company, earning 0.
0% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OKYO leads at 0. 0% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — OKYO or NVCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is OKYO or NVCR better for a retirement portfolio?
For long-horizon retirement investors, OKYO Pharma Limited (OKYO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
79)). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OKYO: -55. 2%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between OKYO and NVCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.